Weight Loss Drug Market Could Reach $150 Billion Globally | Morgan Stanley
The race to develop obesity drugs is entering a new phase. While the first goal was helping people lose weight, the focus is now shifting toward helping them keep the weight off safely and sustainably.
New weight-loss medications known as GLP-1 drugs have delivered impressive results over the past few years. Some treatments can help patients lose up to 20% of their body weight, while Eli Lilly’s experimental drug, retatrutide, recently showed nearly 30% average weight loss after 80 weeks in clinical trials—results approaching those seen with bariatric surgery.
However, experts say bigger weight-loss numbers are no longer the only measure of success. Doctors and researchers are increasingly asking whether additional weight loss is worth the potential increase in side effects.
GLP-1 medications can cause digestive issues such as nausea and stomach discomfort. In some cases, rapid weight loss may also lead to muscle loss, reduced bone density, and a higher risk of gallbladder problems. Because of these concerns, healthcare providers are emphasizing the importance of proper nutrition, exercise, and muscle-preservation strategies while using these medications.
Many experts believe that a large number of patients do not need to lose more than 15% of their body weight to achieve meaningful health benefits. As a result, choosing the right treatment is becoming more personalized and complex.
Drugmakers, including Eli Lilly, Novo Nordisk, Amgen, and Viking Therapeutics, are now exploring new approaches such as combination therapies and more convenient treatment options. Their goal is to improve patient comfort, reduce side effects, and help people stay on treatment for the long term.
The importance of these medications goes beyond weight loss. Studies have shown that some GLP-1 drugs can lower the risk of serious cardiovascular problems, including heart attacks and strokes. Experts say these benefits could help save lives, not just reduce numbers on a scale.
Another key factor will be affordability. The pricing of future drugs, including retatrutide if approved, may influence how widely they are used and who can access them.
In short, the next stage of the obesity-drug revolution is not just about losing more weight. It is about finding the right treatment, managing side effects, making medications affordable, and helping patients maintain healthier lives over the long term.
Featured Snippet Answer
What is the next challenge in obesity treatment?
The next challenge is helping patients maintain weight loss over the long term. Experts say future success will depend on reducing side effects, improving affordability, supporting healthy lifestyle changes, and ensuring patients stay on treatment long enough to gain lasting health benefits.
#WeightLoss #ObesityTreatment #GLP1 #HealthyLiving #MedicalInnovation